IRIS
DI RAIMONDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.191
EU - Europa 14.442
AS - Asia 13.101
SA - Sud America 2.434
AF - Africa 1.045
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 20
Totale 58.263
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.066
SG - Singapore 7.677
RU - Federazione Russa 4.797
CN - Cina 3.566
IE - Irlanda 2.647
IT - Italia 2.640
UA - Ucraina 2.397
BR - Brasile 2.081
CA - Canada 945
CI - Costa d'Avorio 679
VN - Vietnam 569
GB - Regno Unito 358
SE - Svezia 354
DE - Germania 318
IN - India 308
KR - Corea 220
SN - Senegal 141
AR - Argentina 140
PL - Polonia 129
MX - Messico 126
FI - Finlandia 120
NL - Olanda 114
FR - Francia 113
JP - Giappone 109
BD - Bangladesh 95
CH - Svizzera 88
UZ - Uzbekistan 82
ZA - Sudafrica 82
TR - Turchia 70
ES - Italia 67
AT - Austria 66
EC - Ecuador 66
IQ - Iraq 60
HK - Hong Kong 53
CZ - Repubblica Ceca 50
BE - Belgio 47
GR - Grecia 44
ID - Indonesia 39
LB - Libano 37
MA - Marocco 36
CO - Colombia 35
VE - Venezuela 28
PK - Pakistan 27
IR - Iran 26
KE - Kenya 26
AU - Australia 21
CL - Cile 21
IL - Israele 21
LT - Lituania 20
PY - Paraguay 20
AE - Emirati Arabi Uniti 19
BJ - Benin 18
EU - Europa 18
SA - Arabia Saudita 18
JO - Giordania 17
EG - Egitto 16
PE - Perù 16
KZ - Kazakistan 15
BO - Bolivia 14
TN - Tunisia 14
BG - Bulgaria 13
DO - Repubblica Dominicana 12
NG - Nigeria 12
RS - Serbia 12
AZ - Azerbaigian 11
DZ - Algeria 10
NO - Norvegia 9
RO - Romania 9
UY - Uruguay 9
CR - Costa Rica 7
KW - Kuwait 7
MY - Malesia 7
NZ - Nuova Zelanda 7
PS - Palestinian Territory 7
AL - Albania 6
JM - Giamaica 6
NP - Nepal 6
OM - Oman 6
PA - Panama 6
TH - Thailandia 6
BH - Bahrain 5
PH - Filippine 5
SI - Slovenia 5
TT - Trinidad e Tobago 5
BB - Barbados 4
HN - Honduras 3
HU - Ungheria 3
LU - Lussemburgo 3
NI - Nicaragua 3
PT - Portogallo 3
AM - Armenia 2
AO - Angola 2
BF - Burkina Faso 2
BY - Bielorussia 2
DK - Danimarca 2
EE - Estonia 2
GD - Grenada 2
GY - Guiana 2
KG - Kirghizistan 2
LK - Sri Lanka 2
Totale 58.233
Salva come PNG Salva come JPEG
Città #
Dallas 5.125
Singapore 4.290
Santa Clara 2.908
Jacksonville 2.636
Dublin 2.628
Chandler 2.134
Moscow 1.970
Boardman 1.117
Ashburn 1.105
Chicago 960
Catania 909
Nanjing 751
Cambridge 720
Andover 716
Lawrence 715
Abidjan 677
Toronto 654
Houston 525
Hefei 501
Los Angeles 484
Des Moines 423
Beijing 394
San Mateo 386
Nanchang 262
Wilmington 261
Civitanova Marche 229
Seoul 220
New York 210
São Paulo 190
Saint Petersburg 182
Shenyang 180
Ho Chi Minh City 178
Hebei 176
Buffalo 166
Jiaxing 148
Ottawa 148
Dakar 140
Changsha 135
Florence 135
Tianjin 110
Hanoi 106
Rome 105
Council Bluffs 98
Tokyo 97
Grafing 96
Kochi 92
Warsaw 91
Dong Ket 87
Montreal 87
Milan 86
Orem 83
Brooklyn 78
Palermo 74
Stockholm 74
Munich 71
Denver 69
Seattle 67
Boston 63
Poplar 63
San Jose 62
Rio de Janeiro 59
Washington 58
Johannesburg 56
Phoenix 56
Chennai 54
The Dalles 51
Hong Kong 50
San Francisco 49
Belo Horizonte 48
London 48
Columbus 46
Hangzhou 45
Atlanta 44
Redondo Beach 44
Mexico City 43
Brussels 42
Turku 42
Den Haag 39
Lappeenranta 39
Helsinki 38
Norwalk 37
Ankara 36
Mumbai 36
Kunming 35
Falls Church 32
Pune 32
Tashkent 32
Amsterdam 31
Curitiba 29
Jinan 29
Porto Alegre 29
Bremen 28
Bari 27
Brasília 27
Manchester 27
Campinas 25
Guangzhou 25
Messina 25
Brno 22
Guayaquil 22
Totale 38.984
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 272
Childhood neurofibromatosis type 2 (NF2) and related disorders: From bench to bedside and biologically targeted therapies [Neurofibromatosi tipo 2 (NF2) e sindromi correlate in età infantile: dalla biologia molecolare alla pratica clinica e nuove terapie con farmaci biologici] 267
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 210
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload 201
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 198
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 191
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM) 177
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 177
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 165
Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. 163
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 161
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen 159
Il Rasario. Semeiotica medica 159
Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib 159
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 158
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 157
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 153
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 153
A PHASE III STUDY OF ENOXAPARIN VERSUS ASPIRIN VERSUS LOW-DOSE WARFARIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED UP-FRONT WITH THALIDOMIDE BASED-REGIMENS 150
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 148
Hedgehog signaling pathways in multiple myeloma 147
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 147
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 146
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. 145
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 145
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 145
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 145
A PHASE 3, RANDOMIZED CLINICAL STUDY OF AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE AT DIAGNOSIS 144
A snapshot of asparaginase-induced liver insufficiency. 142
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 142
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 141
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 141
NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 140
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 139
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 138
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 137
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 136
A case of high-risk AML in a patient with advanced systemic mastocytosis 136
Acute pre-hepatic portal thrombosis: diagnosis and therapy 136
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol 136
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 136
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 134
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 134
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells 134
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 133
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD 133
ARGINASE 1 IS A MARKER OF MYELOID-MEDIATED IMMUNOSUPPRESSION WITH PROGNOSTIC MEANING IN CLASSIC HODGKIN'S LYMPHOMA 132
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 132
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 131
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 131
A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents 131
BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia 130
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 130
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 129
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 129
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 129
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 129
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 128
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 128
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis 127
A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis 127
A NEW CYTOGENETIC ABNORMALITY, T(1;4) (P22;P16) IN AML M4 PATIENT AFTER CHEMOTHERAPY TREATMENT 127
Mesenchymal stem cells (MSC) promotes tumor microenvironment transformation driving Granulocyte-like Myeloid Derived Suppressor Cells (G-MDSC) activation in Smoldering and Multiple Myeloma patients 126
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 126
Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells 125
Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification 125
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 125
Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over 124
A GLOBAL PROGRESSION RISK SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: THE NEVER-ENDING STORY 124
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia 124
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 123
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma 123
Bone turnover markers in patients with type 1 Gaucher disease 123
A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients 123
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment 122
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 122
Acute myeloid leukemia in elderly patients. 122
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia 122
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia 122
Analysis of metabolic parameters coming from basal and interim PET in hodgkin lymphoma 121
Terapia del mieloma multiplo 118
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 118
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 118
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 117
A Multicentric clinical trial of salvage therapy with thalidomide for patients with advanced relapsed and refractory multiple myeloma 117
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. 117
Multiple Myeloma in 2023 Ways: From Trials to Real Life 116
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 116
Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report 116
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 115
CIRCULATING ARGINASE-1 IN SERUM IS A NOVEL BIO-MARKERIN HODGKIN LYMPHOMA 115
CD200 EXPRESSION ON MYELOMA CELLS AND ANTITUMOR IMMUNITY 115
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 114
A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones? 114
Eventi avversi e trigger C12: Stroke in ospedale 114
The Heme Oxygenase System in Hematological Malignancies 113
A New Method To Evaluate the Prognostic Value of Response to Prednisone Pre-Treatment in Adult (15–60 Yrs) Patients with Acute Lymphoblastic Leukemia: Results of the GIMEMA LAL 2000 Study 113
ANTITUMOR ACTIVITY OF BORTEZOMIB ALONE AND IN COMBINATION WITH TRAIL IN HUMAN ACUTE MYELOID LEUKEMIA C.M.S 112
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 112
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 112
Totale 13.804
Salva come PNG Salva come JPEG
Categoria #
all - tutte 208.952
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 208.952
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.706 0 0 0 0 0 67 540 13 470 8 430 178
2021/20225.171 637 763 22 43 872 42 762 175 524 28 122 1.181
2022/20237.429 743 273 104 503 714 1.384 24 1.266 1.976 58 274 110
2023/20243.154 209 432 133 251 142 514 68 206 15 86 676 422
2024/202512.800 99 2.090 837 448 2.795 1.044 380 521 1.091 1.399 960 1.136
2025/202620.404 1.673 1.754 5.013 1.882 4.775 5.307 0 0 0 0 0 0
Totale 59.320